Patrizia Carpinelli

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index1.5kcitations49works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(28), Cancer-related Molecular Pathways(12), Neuroblastoma Research and Treatments(10), Chronic Myeloid Leukemia Treatments(8), Photosynthetic Processes and Mechanisms(6)

Publications49 total

Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Table 1 from Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358
2023Open Access
Data from Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358
2023Open Access
Supplementary Table 1 from Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358
2023Open Access
Data from Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358
2023Open Access
PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc
International Journal of Molecular Sciences·2021· 12 citedOpen Access
A Focused Small-Molecule Screen Identifies PHA-680626 as an Amphosteric Inhibitor Disrupting the Interaction between Aurora-A and N-Myc
2021Open Access
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
Investigational New Drugs·2017· 40 cited
In-vivo brain H1-MR-Spectroscopy identification and quantification of 2-hydroxyglutarate in L-2-Hydroxyglutaric aciduria
Brain Research·2016· 13 citedOpen Access
Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines
Cancer Research·2016
Combined cisplatin and aurora inhibitor treatment increase neuroblastoma cell death but surviving cells overproduce BDNF
Biology Open·2016· 8 citedOpen Access
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Haematologica·2015· 57 citedOpen Access
517 Identification and characterization of selective MELK kinase inhibitors
European Journal of Cancer·2014
31 N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitor
European Journal of Cancer·2014
Structural Insight into Maternal Embryonic Leucine Zipper Kinase (MELK) Conformation and Inhibition toward Structure-Based Drug Design
Biochemistry·2013· 30 cited
page 1 of 3Next →

Frequent Co-authors

Daniele Fancelli(19), Chiara Soncini(18), Luisa Rusconi(16), Paolo Cappella(14), Maria Laura Giorgini(12), Laura Gianellini(12), Paola Vianello(12), Enrico Pesenti(12), Roberta Ceruti(11), Valter Croci(11), Paola Storici(11), Dario Ballinari(11), Antonella Isacchi(11), Paola Zugnoni(10), Aurelio Marsiglio(10), Gemma Texidó(9), Alexander D. Cameron(9), Maurizio Rocchetti(8), Cristina Alli(8), Anna Degrassi(7)